Piper Sandler Initiates Coverage On Acelyrin with Overweight Rating, Announces Price Target of $68
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Acelyrin (NASDAQ:SLRN) with an Overweight rating and a price target of $68.
May 30, 2023 | 9:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler initiates coverage on Acelyrin with an Overweight rating and a price target of $68.
The initiation of coverage by Piper Sandler with an Overweight rating and a price target of $68 indicates a positive outlook for Acelyrin's stock. This news is likely to attract investors' attention and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100